genprowebdirectory
Facebook Linkedin RSS Twitter Youtube
  • GEN Edge
    • Featured News
    • Multimedia
  • News
    • Insights
  • Topics
    • Artificial Intelligence
    • Bioprocessing
    • Cancer
    • Drug Discovery
    • Genome Editing
    • Infectious Diseases
    • OMICs
    • Translational Medicine
  • Magazine
    • Browse Issues
    • Subscribe
  • Multimedia
    • Summits
    • Webinars
    • GEN Live
    • Learning Labs
    • Podcasts
  • Resources
    • A-Lists
    • eBooks/Perspectives
    • Tutorials
    • Peer-Reviewed Journals
      • GEN Biotechnology
      • Re:Gen Open
    • New Products
    • Conference Calendar
  • Subscribe
    • Get GEN Magazine
    • Get GEN eNewsletters
Search
Facebook Linkedin RSS Twitter Youtube
Sign in
Welcome! Log into your account
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
A password will be e-mailed to you.
Genetic Engineering & Biotechnology News GEN – Genetic Engineering and Biotechnology News
Genetic Engineering & Biotechnology News Genetic Engineering & Biotechnology News
  • GEN Edge
    • Featured News
    • Multimedia
  • News
    • Insights
  • Topics
    • Artificial Intelligence
    • Bioprocessing
    • Cancer
    • Drug Discovery
    • Genome Editing
    • Infectious Diseases
    • OMICs
    • Translational Medicine
  • Magazine
    • Browse Issues
    • Subscribe
  • Multimedia
    • Summits
    • Webinars
    • GEN Live
    • Learning Labs
    • Podcasts
  • Resources
    • A-Lists
    • eBooks/Perspectives
    • Tutorials
    • Peer-Reviewed Journals
      • GEN Biotechnology
      • Re:Gen Open
    • New Products
    • Conference Calendar
  • Subscribe
    • Get GEN Magazine
    • Get GEN eNewsletters
Home 2024

Verve Therapeutics

Top 10 Publicly Owned Gene Editing Therapy Companies
A-Lists

Top 10 Publicly Owned Gene Editing Therapy Companies

Dried Blood COVID Dx, Cryo-Shocked Tumor Cell Delivery Vehicles, Verve Halts Trial, Iambic Starts Trial, and Diagonal Therapeutics Launches
Artificial Intelligence

Dried Blood COVID Dx, Cryo-Shocked Tumor Cell Delivery Vehicles, Verve Halts Trial, Iambic Starts Trial, and Diagonal Therapeutics Launches

StockWatch: Investors Less Forgiving than Analysts as Verve Tumbles
Drug Discovery

StockWatch: Investors Less Forgiving than Analysts as Verve Tumbles

The State of Cell and Gene Therapy 2024
Artificial Intelligence

The State of Cell and Gene Therapy 2024

StockWatch: Verve Investors Accentuate the Negative as Shares Tumble, Then Recover
GEN Edge

StockWatch: Verve Investors Accentuate the Negative as Shares Tumble, Then Recover

Verve’s In Vivo Base Editing Therapy Shows Human Proof-of-Concept Data
Genome Editing

Verve’s In Vivo Base Editing Therapy Shows Human Proof-of-Concept Data

StockWatch: Lilly-Beam Deal for Verve Base Editing Therapies Wows Analysts
Drug Discovery

StockWatch: Lilly-Beam Deal for Verve Base Editing Therapies Wows Analysts

At Chardan Conference, David Liu Foresees First Prime Editing Clinical Trial in 2024
GEN Edge

At Chardan Conference, David Liu Foresees First Prime Editing Clinical Trial in 2024

Frequency Change: Korro Bio Edits Its Message, Rewrites Its Future with Reverse Merger
Drug Discovery

Frequency Change: Korro Bio Edits Its Message, Rewrites Its Future with Reverse Merger

FDA Places Clinical Hold on Verve’s Cardio Base Editing Therapy
Drug Discovery

FDA Places Clinical Hold on Verve’s Cardio Base Editing Therapy

12Page 1 of 2

Read the Digital Edition

June 2024 cover

Explore

  • About GEN
  • Contact GEN
  • GEN Staff
  • Editorial Guidelines
  • Reprints and Permissions
  • Scientific Advisory Board

Advertise

  • Media Kit and Planning Calendar
  • Advertising Terms and Conditions

Resources

  • Get the GEN Magazine
  • Get the GEN Email Newsletter
  • Inside Precision Medicine
  • Privacy Policy
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up